Circulating tumour cells (CTC) are identified exploiting their protein/gene expression patterns or distinct size compared to blood cells. Data on CTC in bladder cancer (BC) are still scarce. We comparatively analyzed CTC enrichment by AdnaTest ProstateCancerSelect (AT) and ScreenCell®Cyto (SC) kits, combined with identification by EPCAM, MUC1, and ERBB2 expression and by cytological criteria, respectively, in 19 nonmetastatic (M0) and 47 metastatic (M+) BC patients, at baseline (T0) and during treatment (T1). At T0, CTC positivity rates by AT were higher in M+ compared to M0 cases (57.4% versus 25%, p = 0.041). EPCAM was detected in 75% of CTC-positive samples by AT, showing increasing expression levels from T0 to T1 (median (interquartile range, IQR): 0.18 (0.07–0.42) versus 0.84 (0.33–1.84), p = 0.005) in M+ cases. Overall, CTC positivity by SC was around 80% regardless of clinical setting and time point of analysis, except for a lower occurrence at T1 in M0 cases. At T0, circulating tumour microemboli were more frequently (25% versus 8%) detected and more numerous in M+ compared to M0 patients. The approach used for CTC detection impacts the outcome of CTC studies. Further investigations are required to clarify the clinical validity of AT and SC in specific BC clinical contexts.
展开▼
机译：利用循环蛋白细胞的蛋白质/基因表达模式或与血细胞相比大小不同来鉴定循环肿瘤细胞（CTC）。关于膀胱癌（BC）中CTC的数据仍然很少。我们比较了通过AdnaTest ProstateCancerSelect（AT）和ScreenCell®Cyto（SC）试剂盒，结合EPCAM，MUC1和ERBB2表达以及根据细胞学标准对19种非转移性（M0）和47种转移性（M +）进行的CTC富集分析。 BC患者，在基线（T0）和治疗期间（T1）。在T0时，与M0病例相比，M +中AT的CTC阳性率更高（57.4％对25％，p = 0.041）。 AT检出75％的CTC阳性样本中的EPCAM，显示从T0到T1的表达水平增加（中位（四分位间距，IQR）：0.18（0.07–0.42）对0.84（0.33–1.84），p = 0.005）。 M +个案例。总体而言，SC的CTC阳性率约为80％，而与临床背景和分析时间点无关，除了 M 0例中T1发生率较低。与 M 0患者相比，在 T 0时，循环肿瘤微栓塞的检出率更高（25％对8％），inem> M +中的数量更多。用于CTC检测的方法会影响CTC研究的结果。需要进一步的研究来阐明AT和SC在特定BC临床环境中的临床有效性。
展开▼
